PSTX: נכסי החברה Poseida

This chart illustrates that the market valuation of Poseida Therapeutics (PSTX) total assets is 297.99. Poseida Therapeutics (PSTX) focuses on developing affordable non-viral gene editing methods to combat tumors. Operational efficiency is maintained by outsourcing manufacturing processes and testing to third-party contractors. Profit stability is ensured through a calibrated transportation system for frozen components via a network of specialized centers.

By scaling the development of allogeneic CAR-T therapies in partnership with Roche, Poseida Therapeutics (PSTX) is accumulating resources, the dynamics of which in the total assets forecast reflect the aggregate of capital and liabilities reverse-calculated via ROA. This indicator allows for the real-time assessment of structural shifts in the company's assets, which is critical for evaluating the issuer's ability to exercise pricing power as healthcare costs decline.